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The pancreatic beta cell is sensitive to even small changes in
PDX1 protein levels; consequently,Pdx1 haploinsufficiency can
inhibit beta cell growth and decrease insulin biosynthesis and
gene expression, leading to compromised glucose-stimulated
insulin secretion. Usingmetabolic labeling of primary islets and
a cultured  cell line, we show that glucose levels modulate
PDX1protein phosphorylation at a novelC-terminalGSK3 con-
sensus that maps to serines 268 and 272. A decrease in glucose
levels triggers increased turnover of the PDX1 protein in a GSK3-
dependent manner, such that PDX1 phosphomutants are refrac-
tory to the destabilizing effect of low glucose. Glucose-stimulated
activation of AKT and inhibition of GSK3 decrease PDX1 phos-
phorylation and delay degradation. Furthermore, direct pharma-
cologic inhibition of AKT destabilizes, and inhibition of GSK3
increasesPDX1proteinstability.Thesestudiesdefineanovel func-
tional role for the PDX1 C terminus in mediating the effects of
glucoseanddemonstrate thatglucosemodulatesPDX1stabilityvia
the AKT-GSK3 axis.
The homeodomain protein PDX1 has been shown to be a
critical regulator of pancreatic development, in both humans
and in mice (1, 2). Whereas genetic ablation or the total func-
tional inhibition of PDX1 results in pancreatic agenesis, haplo-
insufficiency of PDX1 in humans leads to diabetes (3) and is
associatedwith diminished glycemic control inmice (4, 5). Loss
of a single allele of Pdx1 results in increased beta cell death (6)
and a diminished capacity to mount a compensatory response
in some models of insulin resistance (7). Thus, the beta cell is
highly sensitive to total cellular levels of PDX1 protein.
The mechanisms by which PDX1 may regulate glucose
homeostasis have been widely examined. In addition to regu-
lating the insulin gene (8, 9), PDX1 has been shown to activate
Glut2 and glucokinase genes, two key players required for glu-
cose sensing (10, 11). PDX1 can also impact glucose sensing by
influencing expression of mitochondrial metabolic pathways
(12, 13). Accordingly, proteins important in glucose sensing are
down-regulated in Pdx1/mice (5, 7).
In the beta cell, PDX1 is thought to be a direct mediator of
glucose. Several studies have suggested that glucose-stimulated
phosphorylation of PDX1 impacts DNA binding (14, 15) and
the nucleocytoplasmic shuttling of PDX1 (16). Glucose-de-
pendent phosphorylation has also been suggested to increase
the transactivation potential of PDX1 by increasing recruit-
ment of chromatin-modifying proteins such as p300 (17, 18) or
by decreasing binding with histone deacetylases (19). Other
studies suggest direct, glucose-dependent phosphorylation of
PDX1 by specific kinases, including ERK2 1 and 2 (20), and
perhaps p38 MAPK (14, 16). However, to date, the specific
amino acid residues at which glucose-induces PDX1 phosphor-
ylation, within the context of the cell, are not known.
The N terminus of PDX1 harbors a strong transactivation
domain, flanked by theDNA-binding homeodomain (8, 21, 22).
The C terminus of PDX1 has been shown to be a weak transac-
tivation domain (21) and can also recruit inhibitor proteins (19,
23). Here, we show that glucose regulates steady-state levels of
PDX1 protein via a novel phosphorylation site that maps to its
C terminus. Although published studies suggest a stimulatory
effect of glucose on PDX1 phosphorylation (15, 16, 20), our
results show that glucose stimulation of primary islets and
cultured Min6 beta cells decreases PDX1 phosphorylation. A
decrease in C-terminal phosphorylation of PDX1 was associ-
ated with an increase in protein stability and was regulated by
the reciprocal action of AKT and GSK3. Because glucose-stim-
ulated insulin secretion results in autocrine stimulation of the
insulin receptor in the beta cell (24), our results imply that
glucose-dependent insulin secretion regulates steady-state
levels of PDX1 protein in the beta cell.
EXPERIMENTAL PROCEDURES
Reagents—Commercial antibodies used in the study include
mouse anti-hemagglutinin (HA), rabbit anti-AKT, anti-phos-
pho-473-AKT, anti-GSK-3, anti-phospho-21/9-GSK-3a/
(Cell Signaling, Beverly, MA), and rabbit anti-HA antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA). Mouse anti-HA-
agarose beads, and M2-anti-FLAG-agarose beads were from
Sigma. Anti-PDX1 antibodies were a gift fromDr. MarcMont-
miny (25). Protein A-Sepharose-conjugated anti-PDX1 anti-
bodies were generated as described previously (26), and gluta-
thione-Sepharose beads were from Amersham Biosciences.
Horseradish peroxidase-conjugated secondary antibodies
(Jackson ImmunoResearch, West Grove, PA) were detected
using Supersignal West-Pico chemiluminescence reagents
(Pierce). [32P]Orthophosphate, [-32P]ATP, and [35S]methi-
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grant R01DK080147 (to U. S. J.).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S3.
1 Supported by a network grant from The Larry L. Hillblom Foundation and a
Juvenile Diabetes Research Foundation research grant. To whom corre-
spondence should be addressed: 3525 John Hopkins Court, San Diego, CA
92121. E-mail: ujhala@ucsd.edu.
2 The abbreviations used are: ERK, extracellular signal-regulated kinase; HA,
hemagglutinin; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal
bovine serum; WT, wild type.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 285, NO. 5, pp. 3406–3416, January 29, 2010
© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
3406 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 5•JANUARY 29, 2010
 by guest, on M
ay 2, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2009/10/15/M109.006734.DC1.html 
Supplemental Material can be found at:
onine, [35S]cysteine (35S-Met/35S-Cys) were purchased from
MP Biomedicals (Solon, OH). Recombinant GSK-3 was from
New England Biolabs (Ipswich, MA). GSK3 inhibitor II, AKT
inhibitor VIII, and cycloheximide were purchased from EMD
Biosciences, San Diego(full description of inhibitormechanism
available on EMD website), and sequencing grade trypsin was
from Hoffmann-La Roche.
Plasmids—Full-length rat PDX1 was subcloned into
pGEX4T using BamHI/NotI sites and subcloned into both
pcDNA3-HA and pcDNA3-FLAG using XhoI/Xbal sites. PDX1
deletion mutants were generated by PCR, and point mutations
were generated using QuikChange site-directed mutagenesis kit
as per the manufacturer’s instructions (Stratagene, La Jolla, CA).
All constructs were verified by sequencing. GSK3 and AKT
constructs were purchased fromAddgene (Cambridge, MA).
Adult Human Islets—Human adult islets were provided by
Islet Cell Resource Center Basic Science Human Islet Distribu-
tion Program and the Islet Transplant Program, University of
Illinois, Chicago. Islets were purified by handpicking and cul-
tured overnight in CRML supplemented with 10% FBS. Prior to
incubationwith inhibitors, islets were cultured for at least 8 h in
RPMI 1640 medium supplemented with 10% FBS.
Islet Isolation—Islet isolation was performed as described
previously (27). Briefly, pancreata from 3-month-old Sprague-
Dawley rats or C57Bl/6J mice (Jackson Laboratory, Bar Harbor,
ME) were distended with collagenase P (1.5 mg/ml; Roche
Applied Science) or liberase (0.2 mg/ml; Roche Applied Sci-
ence), respectively, and digested at 37 °C for 15 min. Prepara-
tions were washed with Hanks’ buffered salt solution, and the
dissociated islets were purified on Ficoll gradients and cultured
in RPMI 1640 medium supplemented with 10% FBS. For met-
abolic labeling studies, islets from 80 rats were isolated in two
batches, and the pooled islets were cultured overnight in RPMI
medium prior to metabolic labeling.
Cell Culture and Transfections—Min6 cells (passages 15–18)
were grown in DMEM containing 24 mM glucose supple-
mented with 4% batch-tested, heat-inactivated FBS and
50 M -mercaptoethanol. Transfections were performed
using Lipofectamine 2000 (Invitrogen) as per manufacturer’s
instructions. For cycloheximide chase and static treatment,
6-well dishes were transfected with 0.5 g of HA-PDX1 plas-
mid and where indicated with 0.4 g of kinase plasmid. For
phosphorylation studies, Min6 cells in 10-cm dishes were
transfected with 5 g of PDX1 plasmid, and where indicated
3 g of kinase plasmid was included.
Metabolic Labeling and Phosphopeptide Mapping and Phos-
phoamino Acid Analysis—Two groups of 6000 rat islets each,
handpicked and counted, were incubated in low glucose (4mM)
medium containing phosphate-free DMEM, 5% dialyzed
serum, and 0.5 mCi/ml [32P]orthophosphate for 5 h, followed
by a either a 45-min stimulus with glucose to a final concentra-
tion of 24 mM or nonmetabolizable sugar Xylitol (used as a
control to maintain osmotic balance). In case of transfected
Min6 cells, metabolic labeling was conducted in 10-cm dishes
40 h post-transfection. The cells were washed with cold phos-
phate-buffered saline and harvested in SDS-lysis buffer (0.5%
SDS, 50 mMTris, pH 8.0, 1 mM EDTA) containing phosphatase
inhibitors. Lysates were boiled, cooled on ice, and precleared
with pansorbin, and supernatants were used for immunopre-
cipitation with protein A-Sepharose-conjugated PDX1 anti-
bodies or agarose-conjugated anti-FLAG antibodies. Following
SDS-PAGE and autoradiography of the gel, PDX1 protein was
extracted directly from the gel (28) or transferred to nitrocellu-
lose, exposed to film, and then used for PDX1 protein extrac-
tion. To ensure equal loading, the membrane was used for
Western blot analysis for PDX1 protein or for FLAG tag using
alkaline phosphatase color detection system. The gel band
bearing labeled PDX1 was excised, and the protein was ex-
tracted by boiling followed by two overnight extractions in 50
mM NH4HCO3, 1% SDS, and 0.05% -mercaptoethanol, pre-
cipitated using trichloroacetic acid, and digested using trypsin
as described previously (29). PDX1 bands excised from the
membrane were blocked in 1% PVP-40 in 0.1 M acetic acid at
37 °C, washed extensively, and digested using trypsin. Tryptic
peptides generated by either techniquewere oxidized in perfor-
mic acid, washed extensively, and resolved by two-dimensional
analysis using electrophoresis (pH 8.9) in the first dimension,
followed by thin layer chromatography (n-butyl alcohol and
pyridine), and visualized by autoradiography as described pre-
viously (29). After an initial comparison of two-dimensional
maps derived from the two methods of labeled PDX1 extrac-
tion, the membrane-based method was used for the rest of the
study. For phosphoamino acid analysis, labeled phosphopep-
tides identified from the two-dimensional maps were scraped
off the silica plates and hydrolyzed in 6 N HCl at 110 °C; unla-
beled phosphoamino acids were added to the hydrolyzed pro-
tein, and the mixture was separated by two-dimensional high
voltage thin layer electrophoresis at pH 1.9 in the first dimen-
sion and pH 3.5 in the second dimension. Phosphoamino acids
were detected using ninhydrin staining, and radiolabeled phos-
phoamino acids were detected by autoradiography.
In Vitro Kinase Assay—GST-PDX1-WT fusion protein was
expressed using BL21-RIPL cells (Stratagene, La Jolla CA)
and purified using glutathione beads according to the man-
ufacturer’s instructions (Amersham Biosciences). Glutathi-
one S-transferase-bound PDX1-WT was incubated with
recombinant GSK3 (New England Biolabs) for 20 min at
30 °C in kinase assay buffer (200 M ATP, 20 mM Tris-HCl,
pH 7.5, 10 mMMgCl2, 10 mM dithiothreitol) using [-32P]ATP as
described previously (30). Following SDS-PAGE, phosphopro-
teins were detected by autoradiography, followed by two-dimen-
sional tryptic mapping as described above.
Radiolabel Pulse-Chase Studies—Min6 cells were washed
with phosphate-buffered saline and incubated for 1 h in Met/
Cys-free DMEM supplemented with 4% dialyzed serum. The
medium was then replaced with Met/Cys-free DMEM con-
taining 0.25 mCi of 35S-Met/35S-Cys/ml and 4% dialyzed
serum. After a 4-h incubation, the samples were chased with
complete nonradioactive DMEM and harvested every 6 h for
24 h. Cells were lysed and immunoprecipitated using anti-
PDX1 protein A-Sepharose, subjected to SDS-PAGE, and
detected by autoradiography.
Cycloheximide Chase—30 h after transfection, Min6 cells
were cultured in DMEM containing 100 g/ml cycloheximide
for the indicated times. For low glucose, cells were starved in 4
mMglucose for 6 h and replacedwithmediumcontaining either
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low glucose (4 mM glucose) or high glucose (24 mM glucose)
prior to addition of cycloheximide. Chase experiments were
performed twice in triplicate.
Static Culture with Low Glucose—30 h after transfection,
Min6 cells were starved in DMEM containing 4 mM glucose
followed by either 4 or 24mMglucose for 20 h in the presence or
absence of GSK3 inhibitor. HA immunoprecipitates from
transfected cells were resolved by SDS-PAGE and Western
blotting for PDX1. Human and mouse islets were cultured in
RPMI 1640 medium supplemented with 10% FBS and treated
with GSK3, or AKT inhibitor, or both for 20 h and processed
for Western blotting as described below.
Glucose and Insulin Stimulation—Min6 cells were incubated
with HEPES-balanced Krebs-Ringer buffer (KRBH), pH 7.4 (15
mM HEPES, 120 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1.2 mM
KH2PO4, 20 mM NaHCO3, 2 mM CaCl2), supplemented with
0.1% bovine serum albumin and no glucose for 30 min, and 4
mM glucose for a further 4 h, followed by a 20-min stimulation
with either 24 mM glucose or 100 nM insulin in the presence or
absence of AKT inhibitor. The cells were immediately har-
vested and subjected to SDS-PAGE and Western blot analysis.
Immunoprecipitation and Western Blotting—Mammalian
expression vectors encoding HA-tagged fusion proteins were
expressed in Min6, and the immunoprecipitation was per-
formed in NEHN (0.5% Nonidet P-40, 0.5 mM EDTA, 40 mM
HEPES, 150mMNaCl with a complete complement of protease
and phosphatase inhibitors) usingHA beads or anti-PDX1 pro-
tein A-Sepharose. Following SDS-PAGE and transfer, immu-
noblots were probed as indicated. Equal loading was confirmed
by probing for co-transfected internal controls as indicated. For
immunoblots of islet orMin6 cells, the cells were lysed in 50mM
HEPES, 1% SDS, 6 M urea containing a mixture of protease and
phosphatase inhibitors, normalized for total protein using a
micro-BCA assay, and used for Western blotting analysis as
indicated.
Statistics—Densitometry and quantification were performed
using GelEval 1.22 (FrogDance, Dundee, Scotland, United
Kingdom) or ImageQuant (Amersham Biosciences). Statistical
analysis was performed using the Student’s unpaired t test on
data generated from at least three separate experiments. In all
cases, p values less than or equal to 0.05 were considered signif-
icant. Analysis was performed using StatView 5.0 statistical
software.
RESULTS
Glucose Modulates Phosphorylation of PDX1—Glucose-de-
pendent phosphorylation of PDX1 has been suggested by mul-
tiple studies (summarized in Ref. 31), but in vivomapping of a
specific phosphorylation site(s) in PDX1 has not been reported.
Using [32P]orthophosphate, we metabolically labeled rat islets
and examined whether PDX1 phosphorylation status is altered
under low (4 mM) and high (24 mM) glucose conditions. Immu-
noprecipitates of endogenous PDX1 from the radiolabeled
islets were resolved by SDS-PAGE. The band containing PDX1
was excised from the gel and digested with trypsin, and the
resulting peptides were subjected to two-dimensional separa-
tion using thin layer electrophoresis followed by thin layer
chromatography.Autoradiographs from two-dimensional pep-
tide mapping of PDX1 revealed a distinct pattern of phos-
phopeptide spots with two major tryptic phosphopeptides
showing a high level of radiolabel incorporation (Fig. 1A, panels
i and ii, termed spots A and B). Interestingly, a 45-min stimula-
tion of islets with 24 mM glucose (Fig. 1A, panel ii) resulted in
reduced incorporation of radiolabel in both spots A and B com-
pared with results from islets incubated with 4 mM glucose
(panel i). These data suggest that glucose either inhibits phos-
phorylation or promotes dephosphorylation of PDX1.
Metabolic labeling of Min6 insulinoma cells revealed the
same pattern of radiolabel incorporation into spots A and B as
well as decreased incorporation of phosphate after incubation
in high glucose (Fig. 1B, panels i and ii). To localize the phos-
phorylation event to a specific domain, we performed similar
mapping experiments with transfected FLAG-tagged con-
structs encoding PDX1 or its subdomains in metabolically
labeled cells as above. Full-length PDX1 and the PDX1 C ter-
minus (amino acids 213–284) both showed similar patterns in
their respective phosphopeptide maps, suggesting that the two
prominent phosphorylation sites are located in the C terminus
of the PDX1 protein (Fig. 1C, panels i and ii). The two phos-
phopeptides A and Bwere retrieved from the silica plates, acid-
hydrolyzed, and resolved using two-dimensional electrophore-
sis as described previously (Fig. 1C, panels iii and iv). Spots A
and B were both revealed to be phosphoserines, indicating that
glucose regulates the phosphorylation status of two serine res-
idues located in the C terminus of PDX1.
These findings contrastwith previous reports suggesting that
glucose induces phosphorylation of PDX1 (15, 16, 20). How-
ever, none of the studies have mapped the glucose-induced in
vivo PDX1 phospho-acceptor sites, as phosphorylation occurs
within the cell. ERK1 was found to phosphorylate PDX1 in
vitro, at serines 61 and 66 (20). Using a similar in vitro phos-
phorylation approach, we also observed that ERK1 increased
radiolabel incorporation into GST-PDX1 and that mutation of
serines 61 and 66 into alanines significantly reduced incorpo-
ration (supplemental Fig. S1). Furthermore, two-dimensional
peptide maps of ERK1-phosphorylated PDX1 revealed a dis-
tinct pattern of phosphopeptide spots that did not overlap with
the spots observed after labeling of PDX1 inMin6 cells (supple-
mental Fig. S2). These data indicate that glucose-stimulated
phosphorylation of the PDX1C terminus is unlikely to bemedi-
ated by ERK1, and the role of ERK1 and -2 inmodulating PDX1
phosphorylation in vivomerits further investigation.
PDX1 Phosphorylation Maps to a C-terminal GSK3 Consen-
sus Sequence—A closer scrutiny of the potential phospho-
serines in the C terminus of PDX1 revealed a consensus site for
GSK3 (glycogen synthase kinase-3) at positions 268 and 272.
This site is evolutionarily conserved in all mammalian ho-
mologs of PDX1 and is highly homologous to phosphorylation
sites in other known GSK3 substrates (Fig. 2A). FLAG-tagged
WT and mutant PDX1 constructs were transfected into Min6
cells, the cells metabolically labeled, and PDX1 immunopre-
cipitates separated by SDS-PAGE. PDX1 bands were ascer-
tained by autoradiography, and equal loading of protein was
confirmed by Western blotting using color detection (Fig. 2B,
lanes 1–3). Finally, the PDX1 bandswere excised and processed
as described. Mutation of serine 272 resulted in the loss of spot
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B; however,mutation of serine 268 resulted in loss of both spots
A and B (Fig. 2B, panels i–iii). Based on the predicted trypsin
cleavage sites, serines 268 and 272 are contained within the
same peptide. Our data are therefore consistent with spot B
representing a dually phosphorylated peptide as judged by
increased acidity and migration toward the cathode at pH 8.9.
Spot A likely represents phosphorylation at a single site. Inter-
estingly, mutation of serine 268 was sufficient to abolish the
phosphorylation of both sites suggesting a connection between
phosphorylation events at each site.
In vitro, at high concentrations, although inefficient,
GSK3 is capable of phosphorylating both target sites (32).
Therefore, we examined whether bacterially expressed
GST-WT PDX1, or S268A, or S272A-PDX1 mutants can be
directly phosphorylated in vitro using purified GSK3 and
[-32P]ATP. Coomassie staining of total bacterial protein
used in each reaction and a one-dimensional autoradiograph
of the kinase reaction is shown (Fig. 2C, lanes 1–3). As seen
in Fig. 2C (panels i–iii), phosphopeptide mapping revealed
GSK3-induced phosphate incorporation into two tryptic
peptides that resembled the migration of spots A and B. To
ascertain that tryptic peptides generated from direct phos-
phorylation of PDX1 by GSK3 in vitrowere identical to those
generated fromMin6 cells, we resolved a mix of equal counts
of in vitro and in vivo labeled PDX1 peptides by two-dimen-
sional mapping. As shown in Fig. 2D, spots from the in vitro
reaction co-migrated with spots A and B from the in vivo
reaction, indicating that PDX1 may indeed be a substrate for
GSK3 in Min6 cells.
AKT Modulates PDX1 Phosphorylation in Min6 Cells—
GSK3 is activated during fasting and inhibited upon refeeding
by a direct AKT-mediated phosphorylation of GSK3. There-
fore, we examinedwhether PDX1phosphorylationwas affected
by modulating AKT activity. Min6 cells were transfected with
FLAG-PDX1 along with kinase-dead (KD) or constitutively
active myristoylated (Myr) AKT, followed by two-dimensional
mapping of FLAG immunoprecipitates from metabolically
labeled Min6 cells. One-dimensional autoradiograph and
Western blot of the equal PDX1 immunoprecipitated from
each treatment are shown (Fig. 3A, lanes 1–4). The two-dimen-
sional maps reveal that in the presence of AKT2-KD incorpo-
ration of radiolabel was higher in both spots (Fig. 3A, compare
1st and 2nd panels). Importantly, treatment with a cell-perme-
FIGURE 1. Mapping of glucose-regulated PDX1 phosphorylation sites
usingmetabolically labeled rat islets andMin6 cells.A and B, PDX1 immu-
noprecipitates from [32P]orthophosphate-labeled rat islets (A) andMin6 cells
(B) treated with 4 mM glucose (LG) or 24 mM glucose (HG) as indicated were
resolved using SDS-PAGE. Phosphorylated PDX1 (pPDX) was identified by
autoradiography, and tryptic peptide mapping was performed on the
excised labeled bands. Two prominent phosphopeptides labeled as spots A
and B showed a higher incorporation of phosphate in the presence of low
glucose compared with high glucose (panels i and ii). C, phosphopeptide A
and B localize to the C terminus of PDX1. FLAG immunoprecipitates from
[32P]orthophosphate-labeled Min6 cells were transfected with FLAG-
PDX1-WT (panel i) or FLAG-PDX1-C-term (amino acids 213–284) (panel ii).
Phosphoamino acid analysis revealed spots A (panel iii) and B (panel iv) to be
phosphoserines (pS), as inferred by the co-localization of counts/min from
the phosphopeptide hydrolysates with unlabeled ninhydrin-stained phos-
phoamino acid standards (indicated by circles). Loading dyemigration is rep-
resented by X (xylene cyanol) and D (dinitrophenyl-lysine); loading origin is
markedby the closed circle; top edgeof themapmarks chromatography front.
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able inhibitor of GSK3 that specif-
ically competes for the ATP-bind-
ing site in GSK3 suppressed
phosphate incorporation com-
pared with AKT2-KD alone (Fig.
3A, compare 1st and 2nd panels).
Furthermore, constitutively active
Myr-AKT attenuated incorporation
into spot B relative to both vector
control and AKT2-KD (Fig. 3A,
compare 1st, 3rd, and 4th panels).
These data support a model in
which AKT modulates the activity
of GSK3, which is then reflected in
phosphorylation of PDX1.
GSK3 andAKT Inversely Regulate
Total PDX1 Protein Levels inMouse
and Human Islets—Although its
functional role has not been clari-
fied, the C terminus of PDX1 has
been linked with familial diabetes
(33, 34). To determine the func-
tional impact of PDX1phosphoryla-
tion at serine residues 268 and 272
in the C terminus, we first examined
whether phosphomutants impacted
the subcellular localization or the
transactivation potential of PDX1 in
transfected Min6 cells. Under both
low and high glucose conditions,
PDX1 WT and phosphomutants
showed nuclear localization. Simi-
larly, when assessed inGal4 transac-
tivation assays, the transactivation
potential of the phosphomutants
was not different from that of PDX1
WT (data not shown).
GSK3-mediated, phosphoryla-
tion-dependent proteasomal degra-
dation is a prevalent mechanism in
mammalian cells (35–38). There-
fore, we next examined whether
PDX1 protein levels are affected by
pharmacologic inhibition of GSK3
and its upstream regulator kinase
AKT. We found that PDX1 protein
levels were markedly reduced in
mouse (Fig. 3, B and C) as well as
in human islets (Fig. 3,D and E) upon
treatment with an allosteric inhibi-
tor of AKT kinase. By contrast,
pharmacologic inhibition of GSK3
increased PDX1 levels under basal
conditions and also rescued the loss
of PDX1 protein observed upon
pharmacologic inhibition of AKT.
These findings in both mouse and
human primary islets provide
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strong support for a model in which AKT regulates PDX1 pro-
tein levels through its inhibitory effect on GSK3.
AKT Stabilizes and GSK3 Induces Degradation of PDX1
Protein—AKT has been shown to augment Pdx1 transcription
by relieving the repressive effects of FOXO1 (39). To demon-
strate thatAKTalso directly impacts PDX1protein levels,Min6
cells were transfected with cyto-
megalovirus promoter-driven WT
and S268A PDX1 constructs along
with AKT and GSK3 kinases (Fig.
4A). Because mutation of serine 268
resulted in the loss of radiolabel
incorporation into both spots A and
B, the S268A PDX1 mutant was
used for these assays. Consistent
with a model of reciprocal AKT-
GSK3 action, constitutively active
GSK3 resulted in a nearly 70%
decrease in PDX1 protein levels,
whereas overexpression of AKT2
resulted in a 30% increase compared
with PDX1 levels in the presence of
control vector (Fig. 4, A and B).
Accordingly, AKT2-KD led to a 50%
decline in PDX1 protein levels.
Notably, PDX1-S268Awas resistant
to the modulation of kinase activity,
suggesting that the AKT-GSK3 axis
regulates PDX1 protein levels via
Ser-268 phosphorylation.
We next assessed the impact of
phosphorylation on PDX1 half-life.
We first compared the half-life of
PDX1 in Min6 cells using cyclohex-
imide to inhibit translation (Fig. 4,C
and D) or by pulse-chase labeling
with [35S]methionine (supplemen-
tal Fig. S3). The calculated half-life
by both methods was comparable
and assessed to be 8 h. Hence, all
subsequent assessments of PDX1
half-life were made using cyclohex-
imide chase experiments. S268A
was assessed to be more stable than
PDX1-WT with a half-life of 11.5
h (Fig. 4, C and D). GSK3 overex-
pression reduced PDX1 half-life to
5 h (Fig. 4, E and F), whereas the
PDX1-S268A mutant again was
more stable, with an average half-life of 8 h even with overex-
pression of GSK3 (Fig. 4, E andG). By contrast, overexpression
of AKT2 increased the half-life of PDX1 to11 h (Fig. 4,H and
I), which was comparable with the previously observed half-life
S268Amutant. AKT2 overexpression had no further stabilizing
effect on PDX1-S268A (Fig. 4, H and J).
FIGURE 2.PDX1phosphorylationmaps to a C-terminal GSK3 consensus site.A, schematic of PDX1 protein highlighting the ERK (Ser-61 and -66) and newly
identifiedGSK3 (Ser-268 and -272) site (top panel). Also shown is a comparison of the PDX1phosphorylation sitewith knownGSK3 sites (bottompanel). B,PDX1
one-dimensional autoradiography (FLAG-pPDX) andWestern immunoblotting (IB; alkaline phosphatase-baseddetection (top panel)). Lower panels showPDX1
tryptic peptides derived from FLAG-PDX-WT (lane 1 and panel i), FLAG-PDX-S272A (lane 2 and panel ii), and FLAG-PDX-S268A (lane 3 and panel iii). C, one-
dimensional autoradiography (GSTpPDX1), Coomassie staining (GSTPDX1), andphosphopeptidemapsof bacterially expressedGST-PDX1WT (lane 1 andpanel
i), GST-PDX1-S272A (lane 2 and panel ii), and GST-PDX1-S268A (lane 3 and panel iii) phosphorylated in vitro using purified GSK3 and [-32P]ATP. Note loss of
spot B in PDX-S272A mutant (panel ii in B and C) and loss of both spots A and B in PDX-S268A mutant (panel iii in B and C). D, tryptic maps of PDX1
phosphopeptides from in vitroGSK3-labeledGST-PDX1 (panel i), in vivo labeled FLAG-PDX1-WT (panel ii), or amixture of equal counts fromboth (panel iii). Note
the co-migrationof spotAandB from the two reactions inpanel iii.Openarrowheads indicatepoints of reference from in vitromaps and closedarrowheads from
in vivomaps.
FIGURE 3. AKT and GSK3 kinases regulate the phosphorylation and total protein levels of PDX1.
A, one-dimensional autoradiography (FLAG pPDX), Western immunoblotting (IB), and phosphopeptide
maps of FLAG-PDX1 immunoprecipitates from Min6 cells overexpressing AKT-KD in the absence (lane 1
and panel i) or presence of GSK3 inhibitor (lane 2 and panel ii) or overexpressing the vector control (lane
3 and panel iii) or Myr-AKT (lane 4 and panel iv). B–E,Western blots and densitometry of PDX1 protein levels
from extracts of mouse (B and C) and human islets (D and E) in the presence of vehicle (NT, lane 1), AKT
inhibitor (AKT-I, lane 2), GSK3 inhibitor (GSK-I, lane 3), or both (AKT-I GSK-I, lane 4). Histone H3 was used
as a loading control. Densitometric data from three independent experiments were normalized to vehicle-
treated controls (NT) and presented as the mean  S.D. fold difference (*, p  0.05 compared with
untreated islets).
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Inhibition of Phosphorylation at Serine 268 Renders PDX1
Refractory to the Destabilizing Effects of Low Glucose—To
determine whether the ability of glucose to modulate phos-
phorylation of PDX1 at serine 268 is mediated by the reciprocal
actions of AKT and GSK3, we first examined whether glucose
stimulation leads to phosphorylation of AKT and its down-
stream substrate GSK3. Min6 cells were preincubated in low
glucose to reduce basal insulin secretion and AKT activation.
As shown in Fig. 5A, a 20-min stimulus with high glucose (24
mM) increased phosphorylation of bothAKTandGSK3 (lanes 1
FIGURE 4. AKT and GSK3 regulate PDX1 stability via the newly identified C-terminal phosphorylation site. A, Western blotting of anti-HA
immunoprecipitates fromMin6 cells expressing HA-PDX1-WT (lanes 1–4) or HA-PDX1-S268A (lanes 5–8) in the presence of control vector (lanes 1 and 5)
or kinase-dead AKT2 (AKT2-KD, lanes 2 and 6), constitutively active GSK3 (GSK-CA, lanes 3 and 7), or AKT2 (lanes 4 and 8). Densitometric quantification
shown as fold difference in PDX1 protein levels normalized to HA-PDX1-WT (gray bars) or HA-PDX1-S268A (black bars) in the presence of control vector.
C–J, HA immunoprecipitates from Min6 cells expressing HA-PDX1-WT or HA-PDX1-S268A alone (C and D), or in the presence of GSK3 (E–G) or AKT2
(H–J) following a time-dependent cycloheximide (Cx) chase were probed using anti-PDX1 antibodies. Tubulin (Tub) was used as a control. Densitometric
quantification (D, F, and G, and I and J) demonstrates the mean S.D. (n 3) of protein loss at each time point (*, p 0.05 between treatments at the
indicated time point).
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and 2). Both phosphorylation events were inhibited by pharma-
cologic inhibition of AKT kinase activity (Fig. 5A, lane 3). The
effects of glucose stimulation on AKT and GSK3 phosphor-
ylation were comparable with the effect of direct insulin stim-
ulation (Fig. 5A, lane 4). These data suggest that glucose stim-
ulation may activate the AKT kinase pathway through the
autocrine effect of insulin on the beta cell.
Next we examined whether the glucose-stimulated changes
in AKT and GSK3 also impacted total PDX1 protein levels. To
isolate the effect of glucose on PDX1 protein stability from its
reported effect on Pdx1 gene transcription (40), we transfected
early passage Min6 cells with cytomegalovirus promoter-
driven expression vectors encoding HA-taggedWT and S268A
PDX1. HA immunoprecipitation followed byWestern blotting
showed that compared with incubation in high glucose, a 20-h
static incubation with low glucose resulted in a dramatic
decrease in PDX1 protein level (Fig. 5B, lanes 1 and 2). These
effects were reversed by preincubation with the GSK3 kinase
inhibitor (Fig. 5B, lane 4), thus linking the loss of PDX1 protein
under low glucose conditions to the activation of GSK3. Fur-
thermore, co-transfection of AKT2 under low glucose condi-
tions prevented the decrease in PDX1 protein and even boosted
the levels beyond those observed with high glucose (Fig. 5B,
lane 3). Unlike PDX1-WT, protein levels of the S268A PDX1
mutant are maintained even in low glucose conditions and
are not significantly different under high glucose conditions
(Fig. 5B, lanes 5 and 6). These data, presented in a graphic
form in Fig. 5C, underscore the important role of Ser-268
phosphorylation in regulating PDX1 stability in a glucose-
dependent manner.
Finally, we examinedwhether low glucose culture conditions
that result in decreased AKT activation and increased GSK3
activity also impact the half-life of PDX1 protein (Fig. 5D). Low
glucose culture conditions resulted in the rapid loss of PDX1
protein and a calculated half-life of 4.8 h, nearly 40% lower
than the observed PDX1half-life under high glucose conditions
(Fig. 5, D and E). Remarkably, the half-life of the PDX1-S268A
mutant remained unchanged (Fig. 5, D and F). Altering the
glucose level in the culture medium produces changes that are
likely to be complex and to extend beyond the involvement of
AKT and GSK3 alone. However, the important role of serine
268 in modulating the PDX1 half-life with GSK3 overexpres-
sion or under low glucose conditions suggests that GSK3 regu-
lates at least a subset of the effects produced by low glucose
conditions. Our results clearly demonstrate that phosphoryla-
tion of PDX1 on the C-terminal site mapped here has a pivotal
role in regulating PDX1 stability under biologically relevant
conditions.
DISCUSSION
In this study, we demonstrate that within the beta cell,
glucose regulates stability of the PDX1 protein via novel phos-
FIGURE5.Glucose treatmentmodulatesactivityofAKTandGSKkinases to regulatehalf-lifeofPDX1protein.A,Westernblottingofproteinextracts from
Min6 cells incubated in 4 mM glucose (L, lane 1), 24 mM glucose (H, lanes 2 and 3), or 4 mM glucose 100 nM insulin (lanes 4 and 5) in the absence (lanes 2 and
4) or presence of AKT inhibitor (lanes 3 and 5). Cellular extracts were probed as indicated. B, Min6 cells transfected with HA-PDX1-WT (lanes 1–4), along with
control vector (lanes 1–3) or AKT2 (lane 3), or with HA-PDX1-S268A (lanes 5 and 6) were incubated in 4 mM glucose (L, lanes 1, 3, 4, and 5), in the presence or
absence of GSK3 inhibitor (GSK-I) or 24 mM glucose (H, lanes 2 and 6), followed by immunoprecipitation using anti-HA antibodies and Western blotting for
PDX1 protein. Tubulin was used as a control. C, densitometric quantitation of bands (n 3) was normalized to PDX1-WT in 4 mM glucose (LG) and presented
as the mean S.D. fold difference (*, p 0.05 compared with PDX1-WT in 4 mM glucose; ns, not significant). D–F, time-dependent cycloheximide chase of
HA-immunoprecipitates fromMin6 cells transfectedwith either HA-PDX1-WTor HA-PDX1-S268A and incubated in 4mMglucose (LG) or 24mMglucose (HG) as
indicated. Tubulin (Tub) was used as a control. t1⁄2 was determined fromdensitometric quantification (E and F) of time-dependent protein loss presented as the
mean S.D. (n 3). Closed and open circles, PDX1-WT in HG and LG, respectively; closed squares, PDX1-S268A in LG; *, p 0.05 between treatments at the
indicated time point.
Glucose Regulates PDX1 Stability via GSK3/AKT Axis
JANUARY 29, 2010•VOLUME 285•NUMBER 5 JOURNAL OF BIOLOGICAL CHEMISTRY 3413
 by guest, on M
ay 2, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
phorylation sites. Using an unbiased approach employing
[32P]orthophosphate labeling of cells, we found that glucose
regulates phosphorylation of serines 268 and 272 in the C ter-
minus of the PDX1 protein. Furthermore, PDX1 phosphoryla-
tion mapped to a consensus site for GSK3, and both GSK3
activity and PDX1 phosphorylation were reduced upon glucose
stimulation. Consistentwith the ability of AKTkinase to inhibit
GSK3, conditions that increased AKT activity also stabilized
the PDX1 protein. The overall conclusion that we draw from
this study is that glucose stimulation of beta cells is required to
maintain steady-state levels of PDX1 within a narrow range,
and this regulation of PDX1 is coordinated by the GSK3/AKT
axis (see Fig. 6 schematic).
The identification of GSK3 as the C-terminal PDX1 kinase
satisfies multiple criteria that are significant for a protein to be
a substrate of a kinase, including the following: in vitro phos-
phorylation of Ser-268–272 by GSK3; co-migration of phos-
phopeptides in two-dimensional maps from in vitro and in vivo
reactions; inhibition of in vivo phosphorylation by pharmaco-
logic inhibition of GSK3; and the failure of GSK3 to phosphor-
ylate GSK3 consensus site mutants of PDX1 both in vivo and in
vitro (Fig. 2B). Most importantly, phosphorylation-dependent
degradation of PDX1 by GSK3 is consistent with the biologic
role of both proteins in the beta cell. Two-dimensional tryptic
phosphopeptide mapping was the preferred method because it
is both sensitive and reproducible. Also, as shown in this study,
in the absence of a phospho-specific antibody, this method
affords the flexibility of examining phosphorylation under vary-
ing biologic conditions. This method is also more successful at
identifying sites that are phosphorylated at sub-stoichiometric
levels, which can be a limitation with mass spectrometry (41).
Our results of PDX1 phosphorylation and phosphopeptide
mapping differ from published studies that link glucose-stimu-
lated increase in PDX1 transcriptional activity with in vitro
phosphorylation of PDX1 (20). Unlike other studies (14, 15, 20),
we found that phosphorylation of PDX1 was reduced in re-
sponse to glucose stimulation. These comparisons are some-
what limited because glucose-induced PDX1 phosphoacceptor
sites were not mapped in the above-mentioned studies. Serines
268 and 272 together constitute a consensus site for GSK3. In
this regard, a previous report also identified GSK3 as a PDX1
N-terminal kinase (Ser-61 and -66) under conditions of oxi-
dative stress (42). Under the conditions used in our study,
the two-dimensional phosphopeptide maps do not indicate
the presence of an additional GSK3 phosphorylation site in
PDX1. Compared with a canonical GSK3 consensus (see Fig.
2B), the presence of an extra amino acid between Ser-61 and
-66 may suggest an opportunistic GSK3-dependent phos-
phorylation of PDX1 that is specifically associated with
severe oxidative stress.
Our studies show that PDX1 phosphorylation at Ser 268–
272 hastens its degradation. Phosphorylation events expand
the repertoire of structural changes, which in turn serve as
conformational switches for regulated recruitment of pro-
teins. Thus, the possibility exists for as yet unidentified pro-
tein(s) to cooperate with Ser-268–272 in regulating PDX1
protein stability. A shift in PDX1 half-life from 7 to 8 h in
high glucose conditions to 4–5 h under low glucose condi-
tions, or an increase in half-life to nearly 11 h upon overex-
pression of AKT, would suggest that PDX1 levels may be
profoundly impacted under pathophysiologic states that
compromise beta cell glucose uptake. PDX1 function may
also be affected by shifts in glucose levels under physiologic
conditions such as overnight fasting.
In the beta cell, effects of glucose and insulin show exten-
sive overlap (43). Such an overlap can be explained by the
fact that glucose activates the insulin receptor-IRS1/2 path-
way by the autocrine effect of glucose-stimulated insulin
secretion (24, 44). Glucose stimulation has been shown to
promote phosphorylation of AKT (24, 45) and, conse-
quently, AKT-dependent inhibition of its downstream target
GSK3 (46). Similar to PDX1, MafA, and MCL-1, protein sta-
bility is also regulated by glucose-modulated GSK3 activity
(47–49), suggesting that PDX1 protein turnover is regulated
by a prevalent cellular mechanism.
The reciprocal relationship between AKT and GSK3 high-
lights the biologic significance of PDX1 phosphorylation by
GSK3. Indeed, PDX1 levels are reduced in mice with beta
cell-specific overexpression of GSK3 (46) or severe loss of
AKT (50). Similarly, PDX1 levels are augmented with loss of
GSK3 (51) and AKT overexpression as shown here. These
stabilizing effects of AKT on PDX1 would be in addition to
relief of forkhead transcription factor FOXO1-mediated
Pdx1 gene repression. Functionally, insulin-IRS-AKT signal-
ing is required for a normal beta cell glucose response and is
also critical for beta cell survival and growth (50, 52–56).
Because PDX1 action is central to expression of genes
involved in GSIS, and is required for beta cell survival and
growth, it is reasonable to suggest that AKT mediates some
of its effects on beta cell via PDX1. The interdependence
between PDX1 and insulin-AKT action in the beta cell is
supported by two studies, showing that beta cell failure
observed in Irs2/ mice can be rescued either by PDX1
overexpression (57) or by haploinsufficiency of FoxO1 (39).
PDX1 is abundantly expressed in the beta cell, yet even small
changes in PDX1 protein levels impact its function. Brissova et
al. (58) elegantly demonstrate that islets from Pdx1/ mice
retain 68% expression of PDX1 and yet show a clear and signif-
icant compromise in glucose metabolism and calcium mobili-
FIGURE 6. Schematic representation of AKT and GSK3 in glucose-regu-
lated stability of PDX1 protein.
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zation. Taken together, our results suggest the presence of a
self-sustaining loop between glucose stimulation and genes
required for glucose sensing via insulin signaling and PDX1.
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